Table 3 Management of candidemia
Variables | Total cohort (n = 68) | 30-day survivors (n = 31) | 30-day non-survivors (n = 37) | P value |
|---|---|---|---|---|
Initial antifungal agent* | ||||
Micafungin | 41 (60.3) | 19 (61.3) | 22 (59.5) | 1.000 |
Liposomal amphotericin B | 11 (16.2) | 6 (19.4) | 5 (13.5) | 0.531 |
Fluconazole | 7 (10.3) | 2 (6.5) | 5 (13.5) | 0.442 |
Voriconazole | 3 (4.4) | 2 (6.5) | 1 (2.7) | 0.588 |
None during candidemia | 7 (10.3) | 2 (6.5) | 5 (13.5) | 0.442 |
Treatment ≤ 24 h following onset | ||||
Appropriate antifungal therapy alone | 4 (5.9) | 3 (9.7) | 1 (2.7) | 0.324 |
CVC removal alone | 19 (27.9) | 9 (29.0) | 10 (27.0) | 1.000 |
Combined intervention | 5 (7.4) | 2 (6.5) | 3 (8.1) | 1.000 |
Treatment ≤ 48 h following onset | ||||
Appropriate antifungal therapy alone | 9 (13.2) | 3 (9.7) | 6 (16.2) | 0.494 |
CVC removal alone | 18 (26.5) | 8 (25.8) | 10 (27.0) | 1.000 |
Combined intervention | 16 (23.5) | 9 (29.0) | 7 (18.9) | 0.396 |